All News

Ten quiz questions to assess your knowledge on common treatments for heart failure.

Basaglar is indicated to improve glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes.

Loratadine (Alavert) is indicated for runny nose, sneezing, itchy and watery eyes, sinus pressure, and nasal congestion.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.

Enhanced tools in the field of structural biology may reveal new insights into HIV that could lead to a vaccine to protect against the virus progessing to AIDS.

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.

Experts David Pope, PharmD, and Christina Madison, PharmD, FCCP, AAHIVP, discussed the Biden Administration's new test-to-treat plan.

Important evidence about the health effects of e-cigarettes can help shape public health best practices in the United States, the findings of an analysis suggest.

This will increase Moderna’s vaccine catalog to 5, including vaccines against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and HIV, in addition to the immunizations for HSV, and VZV.

Ivosidenib in combination with azacitidine found to significantly improve event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia.

Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

OTC severe sinus medications offer relief to sinus headaches, help to loosen phlegm, reduces sinus pressure and chest congestions, and temporarily reduces fever

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the adverse events patients with ovarian cancer have reported during treatment with rucaparib.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how oncology pharmacy professionals can effectively address fatalistic beliefs and perceptions of cancer-related information among rural adults.

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Novel C. difficile infection (CDI) vaccine shows promise lowering the severity of CDI and in preventing medically attended CDI.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

The health care company’s analysis evaluates non-specialty and specialty drugs, biosimilars, medication affordability, and the cost of administering COVID-19 vaccines.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

The proof-of-concept study is expected to announce topline safety, tolerability, and immunogenicity results by the end of 2022.

The annual conference includes presentations with educational opportunities related to community pharmacies, health system pharmacies, pharmacy law, public health, and more.

Nivolumab (Opdivo) plus platinum-doublet chemotherapy approved for the treatment of adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Study results show that individuals hospitalized for acute heart failure are 36% more likely to experience clinical benefit over 90 days if initiated on the drug following stabilization.

The findings highlight the potential of acetaminophen, non-steroidal anti-inflammatory drugs, and opioid analgesics to treat infectious diseases.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the treatments for hypoactive sexual desire disorder currently available and those not yet approved.

David Drapkin, director of operations and strategic growth at Psychedelics Today, discussed the new Diversity, Equity, and Inclusion Training Fund for clinicians and practitioners in psychedelic medicine.

Durvalumab plus chemotherapy did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.